|
10:53AM CV Therapeutics cut to Neutral at First Albany (CVTX) 13.05 -3.71: -- Update -- First Albany downgrades to Neutral from Buy and cuts their target to $13 from $43 following the FDA briefing documents that implied that it is unlikely that Ranexa can be approved without a substantial new clinical trial. In the documents, the FDA appears to view Ranexa as modestly effective, but notes significant safety risks that are not offset by the product`s demonstrated benefits. Firm believes that the stock could trade as low as the $10-$13 level, but not to the $5.81 net cash value since the drug has been deemed "approvable". |
|
| aus der Diskussion: | +++ CV Therapeutics Inc (CVTX) - Kurssturz +++ |
| Autor (Datum des Eintrages): | kosto1929 (08.12.03 17:37:30) |
| Beitrag: | 6 von 470 (ID:11550075) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |